Observations on the Changing Shape of the Ice Mass and the Determination of the Sublimation End Point in Freeze-Drying: An Application for Through-Vial Impedance Spectroscopy (TVIS).
freeze-drying
primary drying endpoint
process analytical technology
single-vial
thermocouple
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
02 Nov 2021
02 Nov 2021
Historique:
received:
21
08
2021
revised:
12
10
2021
accepted:
13
10
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Models for ice sublimation from a freeze-drying vial rely on the assumption of a planar ice interface up to ~25% loss of ice mass (which is difficult to qualify) whereas single-vial determinations of the sublimation endpoint (by temperature sensors) are based on the point when the observed temperature reaches a plateau, which cannot differentiate between sublimation and desorption-drying. In this work, the real part capacitance of TVIS vial(s) containing frozen water (during sublimation drying) was measured at 100 kHz. This parameter C'(100 kHz) was shown to be highly sensitive to the shape and volume of the ice mass and is therefore a useful parameter for monitoring ice sublimation. By placing a digital camera in front of an isolated TVIS vial containing ice, it was possible to relate the changes in the shape of the ice mass with the changes in the trajectory of the time profile of C'(100 kHz) and determine the point of deviation from a planar ice interface and ultimately determine the point when the last vestiges of ice disappear. Thereafter, the same characteristics of the C'(100 kHz) time-profile were identified for those TVIS vials located out of sight of the camera in a separate full-shelf lyo study, thereby obviating the need for photographic examination.
Identifiants
pubmed: 34834255
pii: pharmaceutics13111835
doi: 10.3390/pharmaceutics13111835
pmc: PMC8624880
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
AAPS PharmSciTech. 2008;9(3):729-39
pubmed: 18561030
J Pharm Sci. 2017 Mar;106(3):770-778
pubmed: 27939928
J Pharm Sci. 1984 Sep;73(9):1224-37
pubmed: 6491939
J Pharm Sci. 2001 Sep;90(9):1345-55
pubmed: 11745787
Eur J Pharm Biopharm. 2013 Apr;83(3):449-59
pubmed: 23159708
AAPS PharmSciTech. 2018 Oct;19(7):2828-2842
pubmed: 30259404
Pharm Dev Technol. 2014 Mar;19(2):148-59
pubmed: 23336717
Dev Biol Stand. 1992;74:137-50; dicussion 150-1
pubmed: 1592164
Pharm Res. 2004 Feb;21(2):191-200
pubmed: 15032301
Eur J Pharm Biopharm. 2020 Jul;152:144-163
pubmed: 32353532
PDA J Pharm Sci Technol. 1995 Nov-Dec;49(6):272-82
pubmed: 8581458
Pharm Dev Technol. 2008;13(5):367-74
pubmed: 18720233
AAPS PharmSciTech. 2017 Oct;18(7):2379-2393
pubmed: 28205144
Eur J Pharm Biopharm. 2018 Sep;130:224-235
pubmed: 29940225
J Pharm Sci. 2019 Jan;108(1):391-398
pubmed: 30077699